Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$UTHR

DatePrice TargetRatingAnalyst
7/11/2024$310.00 → $321.00Overweight → Equal-Weight
Morgan Stanley
2/12/2024$213.00 → $215.00Sell → Neutral
Goldman
2/5/2024$330.00Outperform
Leerink Partners
12/8/2023$309.00Overweight
Wells Fargo
12/6/2022$320.00Buy
UBS
12/5/2022$230.00Sell
Goldman
10/11/2022$288.00Overweight
Morgan Stanley
9/20/2022Underperform
BofA Securities
More analyst ratings

$UTHR
Press Releases

Fastest customizable press release news feed in the world

See more
  • United Therapeutics Named to '100 Best Companies to Work For' in 2025 by Fortune Media and Great Place to Work

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list. "We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For," said Michael Benkowitz, President & Chief Operating Officer of United Therapeutics. "This reflects a key management objective that United Therapeutics be a destination employer, where Unitherians can have their best career while fulfilling our mission to help very sick patients

    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's operations during a fireside chat session at the Leerink Partners Global Healthcare Conference 2025 in Miami Beach. The session will take place on Tuesday, March 11, 2025, from 10:00 a.m. to 10:30 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 da

    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half

    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$UTHR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$UTHR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$UTHR
SEC Filings

See more

$UTHR
Leadership Updates

Live Leadership Updates

See more
  • IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

$UTHR
Financials

Live finance-specific insights

See more
  • United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half

    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 26, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics,

    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3 billion annual revenue run rate in the third quarter," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of our stellar revenue performance, 2025 marks the start of a multi-year cascade of clinical data reads and r

    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$UTHR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more